Special Issue: Nanobody.
Chames P, Rothbauer U
Nos publications
Les équipes du CRCM publient chaque année plus de 130 articles de recherche fondamentale, translationnelle et clinique.
En direct
Journée de rencontres avec les chercheurs de l’UMR 1068 (CRCM) le 07 avril 2020 -
A feed-forward mechanosignaling loop confers resistance to therapies targeting the MAPK pathway in BRAF-mutant melanoma.
Girard CA, Lecacheur M, Ben Jouira R, Berestjuk I, Diazzi S, Prod'homme V, Mallavialle A, Larbret F, Gesson M, Schaub S, Pisano S, Audebert S, Mari B, Gaggioli C, Leucci E, Marine JC, Deckert M, Tartare-Deckert S
NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F, Rypens C, Finetti P, Guille A, Adélaïde J, Monneur A, Carbuccia N, Garnier S, Dirix P, Gonçalves A, Vermeulen P, Debeb BG, Wang X, Dirix L, Ueno NT, Viens P, Cristofanilli M, Chaffanet M, Birnbaum D, Van Laere S
Tetraspanin-6 negatively regulates exosome production.
Ghossoub R, Chéry M, Audebert S, Leblanc R, Egea-Jimenez AL, Lembo F, Mammar S, Le Dez F, Camoin L, Borg JP, Rubinstein E, David G, Zimmermann P
Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity.
Rypens C, Marsan M, Van Berckelaer C, Billiet C, Melis K, Lopez SP, van Dam P, Devi GR, Finetti P, Ueno NT, Bertucci F, Dirix P, Neven P, Vermeulen P, Dirix L, Van Laere SJ
EBV+ diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant-related lymphomas.
Mescam L, Camus V, Schiano JM, Adélaïde J, Picquenot JM, Guille A, Bannier M, Ruminy P, Viailly PJ, Jardin F, Bouabdallah R, Brenot Rossi I, Bohers E, Robe C, Laurent C, Birnbaum D, Wotherspoon A, Gaulard P, Xerri L
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.
Penel N, Mir O, Wallet J, Ray-Coquard I, Le Cesne A, Italiano A, Salas S, Delcambre C, Bompas E, Bertucci F, Saada-Bouzid E, Chaigneau L, Chevreau C, Brodowicz T, Decoupigny E, Vanseymortier M, Laroche L, Taieb S, Le Deley MC, Blay JY
Correction: CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer.
Malleter M, Tauzin S, Bessede A, Castellano R, Goubard A, Godey F, Levêque J, Jézéquel P, Campion L, Campone M, Ducret T, MacGrogan G, Debure L, Collette Y, Vacher P, Legembre P
Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy.
Amatore F, Gorvel L, Olive D
Lambert S, Borde V, Charbonnier JB, Dantzer F, Espéli O, Guirouilh-Barbat J, Llorente B, Legube G, Prioleau MN, Radicella P